News

Novo Nordisk wins case to kick knockoff Ozempic off the market, but it may not last
Novo Nordisk scored a legal win against compounders of its blockbuster GLP-1 drugs. But it may not end the copycats.
Novo Nordisk: Examining Tariff And Pricing Risks
Novo Nordisk remains financially strong, but pricing pressures and CagriSema challenges limit near-term upside. Find out why ...
Stocktwits on MSN23h
Novo Nordisk Wins Another Legal Battle Against Compounding Of Wegovy, Ozempic: Retail’s Bullish
Novo Nordisk (NVO) announced on Friday that it has secured a legal victory against compounders selling unauthorized versions ...
Morningstar18h
American Funds New Perspective A
The strategy was also overweight healthcare and industrials thanks to pharmaceutical picks such as Novo Nordisk NVO and aerospace companies like Airbus. The strategy's focus on multinational ...